Additionally, mutations that trigger RET activity led to multiple endocrine neoplasia type 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma (FMTC) thyroid cancers (Vidal et al., 2005). Here, RET is linked to multiple endocrine neoplasia type 2.